A new study from King’s College London has introduced a promising drug that could help save people during heart attacks by stopping one of the most dangerous problems: a sudden, deadly change in heart rhythm.
The drug is called OCT2013, and early results suggest it may work in a safer and more precise way than older treatments.
Heart disease is one of the leading causes of death around the world. In the United Kingdom alone, around 100,000 people die from heart attacks each year. Many of these deaths happen very quickly, often before an ambulance can arrive.
One of the main reasons for this is a condition called ischemia. This happens when a blood vessel that supplies the heart becomes blocked, which means the heart muscle does not get enough oxygen.
When the heart muscle is starved of oxygen, it can become unstable. One of the most dangerous results is a problem called ventricular fibrillation. This is when the heart starts beating in a fast and chaotic way instead of pumping blood properly.
When this happens, the heart can no longer send blood to the brain and the rest of the body. Without quick treatment, this condition can lead to sudden death within minutes.
For many years, scientists have been trying to find drugs that can stop this dangerous heart rhythm. One drug that has been studied a lot is lidocaine. It can help control the heart’s electrical signals and reduce the risk of ventricular fibrillation.
However, lidocaine has a major problem. It affects not only the damaged part of the heart but also healthy areas and even the nervous system. Because of these side effects, it can only be given carefully in hospitals through a vein. This limits its use, especially in emergencies that happen outside the hospital.
To solve this problem, researchers developed OCT2013. This new drug is designed to behave in a smarter way. It has a structure that is similar to lidocaine, but it does not act in the same way in the body. Instead of working everywhere, it stays inactive until it reaches areas of the heart that are low in oxygen.
In the study, scientists tested OCT2013 using a model that mimics heart attacks in rats. They wanted to see if the drug could prevent sudden death caused by dangerous heart rhythms. The results were very encouraging.
The drug changed into an active form, similar to lidocaine, only in the parts of the heart that were affected by ischemia. In other words, it turned on only where it was needed.
This targeted action is important because it means the drug does not interfere with healthy parts of the heart or other systems in the body. As a result, it avoids the serious side effects that have limited older drugs. At the same time, it still helps stabilize the heart’s electrical activity in the damaged area, reducing the risk of ventricular fibrillation.
This kind of approach represents a new way of thinking about medicine. Instead of affecting the whole body, the drug responds to specific conditions, such as low oxygen levels. This makes treatment both safer and more effective.
If future studies confirm these results, OCT2013 could become a drug that people at high risk might use even outside the hospital, which could help save lives during the critical early moments of a heart attack.
The research was led by Dr. Mike Curtis and his team and was published in the British Journal of Pharmacology. While more work is needed before the drug can be used in people, the findings are an important step forward. They show that it may be possible to design treatments that act only when and where they are needed.
This study brings new hope in the fight against sudden cardiac death. By focusing on both safety and effectiveness, it opens the door to better ways of protecting the heart when every second counts.
If you care about heart health, please read studies about how eating eggs can help reduce heart disease risk, and Vitamin K2 could help reduce heart disease risk.
For more information about heart health, please see recent studies about how to remove plaques that cause heart attacks, and results showing a new way to prevent heart attacks, strokes.
Copyright © 2026 Knowridge Science Report. All rights reserved.
